Please assess the completion status of the following clinical trial:

Trial Title: Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old \< Age \< 75 years old with prior diagnosis of achalasia via manometry and/or radiographically~Exclusion Criteria:~* \< 18 years old or \> 75 years old~* History of hypertension not controlled on oral medications (blood pressure \> 160/100 mm Hg)~* No prior history of hypertension with a blood pressure \> 160/100 mm Hg~* History of bladder outlet obstruction~* History of angioedema~* Pregnant or breast-feeding women: Women between 18 and 40 years old who are enrolled in the study will be required to use a form of birth control during the study~* Patients currently receiving certain medications (digoxin, warfarin, any overactive bladder medications, thioridazine, flecainide, propafenone, phosphodiesterase inhibitors)~* Patients with prolonged QTc interval or risk factors to develop it:~  * Baseline QTc on EKG of \> 450 milliseconds~ * History of additional risk factors for Torsades de Pointes (heart failure, family history of long QT syndrome)~ * Concomitant medications that prolong the QTc interval: ranolazine, sotalol, dofetilide, procainamide, disopyramide, propafenone, azole antifungals, fluoroquinolones, macrolide antibiotics, HIV antiretrovirals, chemotherapy, beta-2 agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors~* Prior surgeries for achalasia~* \< 2 months since last endoscopic botulinum toxin injection into LES or endoscopic dilation~* Stage 4 Chronic kidney disease (severe renal impairment with GFR 15-29 ml/min), Stage 5 Chronic Kidney disease (GFR \< 15 ml/min or on dialysis)~* Childs Pugh B (moderate) or C (severe) Cirrhotic (hepatic impairment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mirabegron (Type: EXPERIMENTAL): Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).